These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23531031)

  • 1. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells.
    Pugliese M; Fortunati N; Germano A; Asioli S; Marano F; Palestini N; Frairia R; Boccuzzi G; Catalano MG
    Thyroid; 2013 Jul; 23(7):838-46. PubMed ID: 23531031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
    Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
    J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
    Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
    Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
    Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 9. Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
    Choi YJ; Lee JE; Ji HD; Lee BR; Lee SB; Kim KS; Lee IK; Chin J; Cho SJ; Lee J; Lee SW; Ha JH; Jeon YH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer.
    Liu L; Li D; Chen Z; Yang J; Ma Y; Cai H; Shan C; Lv Z; Zhang X
    Cell Physiol Biochem; 2017; 43(3):905-914. PubMed ID: 28957796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
    Furuya F; Shimura H; Suzuki H; Taki K; Ohta K; Haraguchi K; Onaya T; Endo T; Kobayashi T
    Endocrinology; 2004 Jun; 145(6):2865-75. PubMed ID: 14976143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
    Zarnegar R; Brunaud L; Kanauchi H; Wong M; Fung M; Ginzinger D; Duh QY; Clark OH
    Surgery; 2002 Dec; 132(6):984-90; discussion 990. PubMed ID: 12490845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene.
    Presta I; Arturi F; Ferretti E; Mattei T; Scarpelli D; Tosi E; Scipioni A; Celano M; Gulino A; Filetti S; Russo D
    BMC Cancer; 2005 Jul; 5():80. PubMed ID: 16029487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
    Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer.
    ElMokh O; Taelman V; Radojewski P; Roelli MA; Stoss A; Dumont RA; Dettmer MS; Phillips WA; Walter MA; Charles RP
    J Nucl Med; 2019 Jul; 60(7):917-923. PubMed ID: 30464041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors.
    Puppin C; D'Aurizio F; D'Elia AV; Cesaratto L; Tell G; Russo D; Filetti S; Ferretti E; Tosi E; Mattei T; Pianta A; Pellizzari L; Damante G
    Endocrinology; 2005 Sep; 146(9):3967-74. PubMed ID: 15919754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
    Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
    J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.
    Xu S; Cheng X; Wu J; Wang Y; Wang X; Wu L; Yu H; Bao J; Zhang L
    J Mol Cell Biol; 2022 Jan; 13(11):791-807. PubMed ID: 34751390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
    Kitazono M; Robey R; Zhan Z; Sarlis NJ; Skarulis MC; Aikou T; Bates S; Fojo T
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3430-5. PubMed ID: 11443220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
    Mitrofanova E; Unfer R; Vahanian N; Link C
    Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.